The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
CLONEVO: Preoperative abemaciclib for cisplatin-ineligible muscle-invasive bladder cancer (MIBC) with molecular response assessment.
 
Bishoy Faltas
Stock and Other Ownership Interests - Freenome; OneThree Biotech; Owkin
Honoraria - UroToday
Consulting or Advisory Role - Astrin Biosciences; BostonGene; Immunomedics/Gilead; Merck; QED Therapeutics
Research Funding - Lilly
Patents, Royalties, Other Intellectual Property - Immunomedics/Gilead
 
Mohamed Osman
No Relationships to Disclose
 
Mark Evans
Employment - Caris Life Sciences
Stock and Other Ownership Interests - Caris Life Sciences
Travel, Accommodations, Expenses - Caris Life Sciences
 
Daniel Margolis
Consulting or Advisory Role - Promaxo. C. Tempany, Profound Medical, MedScape
 
Cora Sternberg
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb/Medarex; Foundation Medicine; Genzyme; Gilead Sciences; Immunomedics; IMPAC Medical Systems; Incyte; Janssen Oncology; Medscape; Merck; MSD; Pfizer; Roche; UroToday
Travel, Accommodations, Expenses - Merck
 
Jones Nauseef
Employment - Convergent Therapeutics
Honoraria - Pfizer
Consulting or Advisory Role - AIQ Solutions; Bayer; NextCure; Pfizer
Travel, Accommodations, Expenses - Digital Science Press; Pfizer
 
Ana Molina
Consulting or Advisory Role - Eisai, Exelixis and Janssen.
 
David Nanus
Honoraria - Genentech
Consulting or Advisory Role - AstraZeneca; Janssen Scientific Affairs
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Clovis Oncology (Inst); Exelixis (Inst); immumedics (Inst); Janssen (Inst); Novartis (Inst); pfizer (Inst); Sagimet Biosciences (Inst); Zenith Epigenetics (Inst)
 
Neal Patel
No Relationships to Disclose
 
Rohit Jain
Honoraria - Curio Science; DAVA Oncology; FLASCO; MJH Life Sciences
Consulting or Advisory Role - AVEO; Bristol-Myers Squibb; EMD Serono; Gilead Sciences; Sanofi
Research Funding - Bristol Myers Squibb; Gilead Sciences; NCI
Travel, Accommodations, Expenses - Bristol Myers Squibb Foundation; DAVA Oncology; FLASCO; Sanofi
 
Juan Miguel Mosquera
No Relationships to Disclose
 
Philip Abbosh
Stock and Other Ownership Interests - Abyost PHarmaceuticals
Consulting or Advisory Role - ArTara Therapeutics
Research Funding - Adaptive Biotechnologies; Janssen Oncology (Inst); natera
Patents, Royalties, Other Intellectual Property - Intravesical imidazolium compunds; novel kidney cancer vaccine (Inst); urine biomarkers patent application
 
Manuel Hidalgo
Leadership - BMS; Guardant Health
Stock and Other Ownership Interests - Champions Oncology; InxMed; Nelum Corp.
Honoraria - Champions Oncology; Velavigo; Velavigo
Consulting or Advisory Role - InxMed; Oncomatrix
Research Funding - Incyte; Ranok Therapeutics; TopAl
Patents, Royalties, Other Intellectual Property - Royalties from Myriad for PALB2 patent
Travel, Accommodations, Expenses - BMS; Guardant Health
 
Nicolas Robine
No Relationships to Disclose
 
William Hooper
No Relationships to Disclose
 
Olivier Elemento
Stock and Other Ownership Interests - Freenome, OneThree Biotech, Owkin and Volastra Therapeutics
Honoraria - Pionyr Immunotherapeutics and Champions Oncology
 
Namrata Peswani
No Relationships to Disclose
 
Suzanne Cole
Research Funding - Merck (Inst)
 
Douglas Scherr
Research Funding - Urogen Pharma, Cepheid, Anchiano and CryoLife
 
Scott Tagawa
Stock and Other Ownership Interests - Convergent Therapeutics
Consulting or Advisory Role - 4D Pharma; Abbvie; AIkido Pharma; Ambrx; Amgen; Astellas Pharma; Bayer; Bicycle Therapeutics; Blue Earth Diagnostics; Boston Scientific; Clarity Pharmaceuticals; Clovis Oncology; Convergent Therapeutics; Daiichi Sankyo; Dendreon; Endocyte; Exelixis; Genentech; General Electric; Genomic Health; Gilead Sciences; Hookipa Pharma; Immunomedics; Janssen; Karyopharm Therapeutics; Lantheus Medical Imaging; Medivation; Merck; Myovant Sciences; Novartis; Pfizer; POINT Biopharma; QED Therapeutics; Regeneron; Sanofi; Seagen; Telix Pharmaceuticals; Tolmar; TransThera Biosciences
Research Funding - Abbvie (Inst); Ambrx (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AVEO (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Clarity Pharmaceuticals (Inst); Clovis Oncology (Inst); Dendreon (Inst); Endocyte (Inst); Exelixis (Inst); Genentech (Inst); Immunomedics (Inst); Inovio Pharmaceuticals (Inst); Janssen (Inst); Janux Therapeutics (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Medivation (Inst); Merck (Inst); Millennium (Inst); Newlink Genetics (Inst); Novartis (Inst); POINT Biopharma (Inst); Progenics (Inst); Rexahn Pharmaceuticals (Inst); Sanofi (Inst); Stem CentRx (Inst); Telix Pharmaceuticals (Inst)
Patents, Royalties, Other Intellectual Property - Patent Royalty from Immunomedics / Gilead
Travel, Accommodations, Expenses - Amgen; Astellas Pharma; Immunomedics; Merck; Sanofi; Telix Pharmaceuticals
(OPTIONAL) Uncompensated Relationships - ATLAB Pharma; Phosplatin Therapeutics
 
Weill Cornell EIPM
No Relationships to Disclose